ABSTRACT
La combinación de tratamiento antitrombótico anticoagulante/antiagregante) que deben llevar aquellos pacientes con FA que sufren un SCA y/o deben someterse a ICP no está claro. La asociación de anticoagulación oral con un inhibidor de P2Y12 y aspirina, lo que se denomina triple terapia antitrombótica (TAT) asocia un elevado riesgo de hemorragia. Por otro lado, la terapia antitrombótica dual (DAT) sin aspirina conlleva un riesgo todavía desconocido de eventos isquémicos.(1) El tratamiento debe equilibrar el riesgo isquémico y hemorrágico alcanzando un beneficio clínico neto óptimo. El objetivo de esta revisión es establecer unas pautas más claras de tratamiento en estos pacientes. Analizamos 2 estudios observacionales previos para sentar el punto de partida y 5 ECA que incluían un total de 11532 pacientes. En ellos se comparó la DAT vs. TAT, en pacientes con FA que sufren un SCA y/o son sometidos a ICP.La DAT asoció menor tasa de sangrados frente a la TAT sin aumentar los eventos isquémicos. Sin embargo, ningún ensayo consiguió la suficiente potencia estadística para evaluar de forma consistente los resultados isquémicos de eficacia. De las distintas terapias, mostraron mejores resultados de eficacia aquellas que emplearon DAT frente a TAT y ACOD frente a AVK. Conclusión: En pacientes con FA que sufren un SCA y/o deben someterse a ICP, el régimen de DAT asocia menos eventos hemorrágicos, sin diferencias significativas en cuanto a eventos isquémicos; El uso de ACOD muestra un mejor perfil de beneficio frente a los AVK, por lo que son de preferencia.(AU)
The combination of antithrombotic treatment (anticoagulant / antiplatelet) that those who AF patients who have ACS and / or must undergo PCI is unclear. The association of oral anticoagulation with a P2Y 12 inhibitor and aspirin, called triple antithrombotic therapy (TAT) is associated with a high risk of bleeding. On the other hand, dual antithrombotic therapy (DAT) without Aspirin carries a still unknown risk of ischemic events.(1) Treatment must balance the ischemic and hemorrhagic risk reaching an optimal net clinical benefit. The purpose of this review is to establish clearer treatment guidelines in these patients. We analyzed 2 previous observational studies to establish the starting point and 5 RCTs that included a total of 11,532 patients. In them, DAT vs. TAT, in patients with AF who suffer from ACS and / or undergo PCI.DAT was associated with a lower rate of bleeding compared to TAT without increasing ischemic events. Without However, no trial achieved sufficient statistical power to consistently assess the ischemic efficacy results. Of the different therapies, they showed better efficacy results those that used DAT versus TAT and ACOD versus VKA. Conclusion: In patients with AF who suffer an ACS and / or must undergo PCI, the DAT regimen associates fewer bleeding events, without significant differences regarding ischemic events; The use of ACOD shows a better profile of benefit versus AVK, so they are preferred.(AU)
Subject(s)
Humans , Fibrinolytic Agents/therapeutic use , Atrial Fibrillation/diagnosis , Patients , Percutaneous Coronary Intervention , Anticoagulants/therapeutic use , Atrial Fibrillation , Myocardial Ischemia/diagnosis , Myocardial Ischemia/drug therapy , Drug Therapy , Drug CombinationsABSTRACT
Objective To investigate the significances of monitoring urine neutrophil gelatinase -associated apolipoprotein (NGAL)and kidney injury molecule -1 (KIM-1)levels before and after coronary intervention in early predication of contrast -induced nephropathy.Methods The clinical data of 249 patients with coronary heart disease undergoing percutaneous coronary intervention were collected.All patients were divided into contrast -induced nephropathy group(n =21 )and non -contrast -induced nephropathy group(n =228)according to whether had contrast -induced nephropathy.Before surgery and 4h,12h,24h,48h,72h after surgery,the levels of serum creatinine were tested.Before surgery and 4h,12h,24h,48h after surgery,the levels of urinary NGAL and KIM-1 were detected by using enzyme -linked immunosorbent assay(ELISA).Results Compared with before surgery,the serum creati-nine level of contrast -induced nephropathy patients after surgery 48h[(101.7 ±20.3)μmol/L]was elevated,the difference was statistically significant(t =15.972,P <0.05).Compared with before surgery,the urinary NGAL levels of contrast -induced nephropathy patients after surgery 4h ~48h were (12.3 ±1.6)μg/L,(14.5 ±1.5 )μg/L, (14.1 ±1.2)μg/L and (14.3 ±1.4)μg/L,which were significantly elevated(t =8.672,11.817,15.942 and 17.641,all P <0.05),and the urinary KIM-1 levels after surgery 24h and 48h were (5.1 ±0.9)μg/L and (5.5 ± 1.3)μg/L,which were elevated,the differences were statistically significant(t =9.672,14.381,all P <0.05).The urinary NGAL levels of contrast -induced nephropathy patients after surgery 4h ~48h were higher than non -contrast-induced nephropathy patients,and the urinary KIM-1 levels after surgery 24h and 48h were higher than non -contrast -induced nephropathy patients,the differences were statistically significant(t =17.838,19.370,13.996, 18.172,2.792,3.307,all P <0.05).Pearson correlation analysis showed that the urinary NGAL levels after 4h and urinary KIM-1 levels after 24h were positively correlated with serum creatinine levels after surgery 48h(r =0.698, 0.576,all P <0.05).ROC curve analysis showed that urinary NGAL levels in predicting contrast -induced nephrop-athy,the area under the curve was 0.963 (95% CI:0.931 ~0.995 ),sensitivity was 85.7%,and specificity was 94.3%,for urinary KIM-1 levels,those were 0.839 (95%CI:0.768 ~0.909),81.0% and 72.8%.Conclusion The urinary NGAL levels of contrast -induced nephropathy patients after interventional treatment 4h were increased, and the urinary KIM-1 levels appeared increased after surgery 24h,which were earlier than serum creatinine.They were expected to be early indicators for determining acute kidney injury and predicting contrast -induced nephropathy after intervention treatment.
